Oral adverse effects for escitalopram (Cipralex®) [2]

British Journal of Dermatology

Volumn 156, Issue 5, 2007, Pages 1046-1047

  Aframian, D J ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; ETHINYLESTRADIOL PLUS GESTODENE; LUBRICATING AGENT; ORAL CONTRACEPTIVE AGENT;

ADULT; ANAMNESIS; CASE REPORT; CAUCASIAN; CLINICAL FEATURE; DEPRESSION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERPIGMENTATION; LETTER; LICHENOID ERUPTION; LOW DRUG DOSE; MOUTH EXAMINATION; MOUTH LESION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SKIN MANIFESTATION;

ADULT; CITALOPRAM; DEPRESSIVE DISORDER; FEMALE; HUMANS; LICHENOID ERUPTIONS; LIP DISEASES; MOUTH DISEASES; MOUTH MUCOSA; PIGMENTATION DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 34247346562     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07767.x     Document Type: Letter

References (4)

1. Litt JZ. Litt's Drug Eruption Reference Manual, 11th edn. London:Taylor & Francis, 2005 195.
2. Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs 2005 65:2379 404.
3. Scully C, Bagan JV. Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med 2004 15:221 39.
4. Inaloz HS, Kirtak N, Herken H et al. Citalopram-induced photopigmentation. J Dermatol 2001 28:742 5.